Do a search on the AFM-Telethon website.
Through its annual calls for proposals, each year AFM-Telethon supports new research projects in France and abroad, particularly for young researchers. After assessment by its Scientific advisory board, the Association finances the most relevant or most innovative initiatives in the development of therapeutic concepts and the understanding of the causes of rare and neuromuscular diseases. Discover its calls for proposals and financing opportunities.
AFM-Telethon is launching a two-year strategic research programme with Professor Drew Weissman, recipient of the 2023 Nobel Prize in Physiology or Medicine for his groundbreaking work on messenger RNA, and Professor James Dowling, a leading expert in neuromuscular diseases, at the University of Pennsylvania. The aim is to develop lipid nanoparticles capable of targeting muscle tissue while minimising uptake by the liver.
Documents to discover everything about the latest progress in research for a given disease or group of diseases. See the publications in English.
Research into glycogen storage disease type III is gaining momentum, with advances across many areas and active contributions from Généthon and I-Stem.
A new design, enriched content, simpler, smoother and more intuitive navigation, and an innovative AI-powered search engine… The Institute of Myology has completely redesigned its website to provide users with a more seamless and effective browsing experience. The new site makes the expertise and knowledge of this centre dedicated to muscle and muscle diseases more accessible than ever.
The 9th international congress dedicated to muscle biology and neuromuscular diseases, MYOLOGY 2027, will take place in Strasbourg, France, from May 10 to 13, 2027. Registration and abstract submissions are now open on the dedicated website.
Discover Cure Through Innovation 2026, the reference brochure presenting at a glance the core missions, commitments, and achievements of AFM-Téléthon. An essential document to grasp the diversity of its actions and the emergence of an innovative medicine born from 66 years of fighting.
AFM-Telethon has long struggled to defend the rights of patients, of people living with disabilities, and to obtain recognition for rare diseases. As a driver of research and innovation, it defends an ambitious national policy.
Committed to scientific research as well as to the support of patients and their families, AFM-Telethon acts independently, guided only by the urgency of the progressive disease, for the benefit of patients.
Transparent and meticulous management: in 2025, AFM-Telethon committed €106.5 M to its social missions, in addition to €42.6 M in advances and investment for the Cure mission.
The AFM-Telethon has chosen to implement a strategy of public interest to benefit as many people as possible.
While the first gene therapy drugs are obtaining marketing authorization and being made available to patients, the challenge of industrializing their production is a crucial one.
Created in 1987 at the initiative of Bernard Barataud and Pierre Birambeau, both fathers of sons suffering grom Duchenne muscular dystrophy, the Telethon combines, since its first edition, a TV program and dozen of thousands of events throughout France. Discover the birth of this unique fundraising event.
Peeling an apple. Lifting your arms. Walking. Smiling. Breathing. These routine actions use muscles and we accomplish them without thinking. But with neuromuscular diseases, the muscles are attacked and movement is prevented. In order to better treat them, AFM-Telethon wants to make myology a separate discipline.
At each Telethon, thousands of volunteers and partners join forces to organize fundraising initiatives all over France and abroad. This participation is unique by its sheer scale.